pharmaphorum

DECEMBER 23, 2022

In 2022, life sciences companies have been hard at work breaking down silos to better serve patients and healthcare professionals (HCPs). And in 2023, these investments will hopefully pay off. Leading companies will empower their teams to act quickly, compliantly, and with a unified view of the HCP.”.

Marketing 105

Marketing Sales Medical Patients 105

Pharmaceutical Technology

NOVEMBER 3, 2022

The Australian Department of Health and Aged Care published a similar statement on August 25, stating that tenecteplase shortages will likely affect the country until the end of 2023. Also, substitution can lead to further shortages, he adds. Dobutamine is used in the acute treatment of heart failure.

Medicine 111

Medicine Manufacturing Pharmacology Healthcare 111

European Pharmaceutical Review

FEBRUARY 22, 2023

1 Used to treat a range of chronic diseases (eg, diabetes, rheumatoid arthritis, psoriasis, Crohn’s disease, haemophilia, etc), it is projected that the sales of biologics will rise from $380 billion in 2022 to $416 billion in 2023, and to almost $600 billion in 2027. This trial is anticipated to begin in the second half of 2023.

Food and Drug Administration 105

Food and Drug Administration Manufacturing Safety Pharmaceutical 105

European Pharmaceutical Review

MAY 2, 2023

Cancer remains a global threat with around 10 million people dying from the disease each year worldwide, making it the second leading cause of death. Previously, he spent more than 10 years at Roche in multiple positions within medical affairs. cited 2023 Apr 4]. 2019 [cited 2023 Apr 4]. cited 2023 Apr 4].

Patients 105

Patients Medicine Marketing Medical 105

Medgadget

FEBRUARY 17, 2023

Thanks to kind support from Biomed Israel , the leading international Life Science and HealthTech conference in Israel (see more below), we met with Ronan Castro, the CEO of Human Xtensions at the company’s offices in Netanya, Israel. More info can be found at the Biomed Israel website.

Physicians 80

Physicians Engineering Leads Side effects 80

Pharmaceutical Technology

NOVEMBER 21, 2022

Meanwhile, the drug's closest TIL competitor, Iovance Biotherapeutics’ lifileucel, has begun a rolling BLA for advanced melanoma patients and could reach the market as early as Q3 2023. In April this year, the FDA provided new feedback on the potency assays, which Iovance indicated will be addressed in the latest BLA.

Manufacturing 59

Manufacturing Food and Drug Administration Medical science Patients 59

European Pharmaceutical Review

DECEMBER 28, 2023

Can you share some highlights from the data presented at ASH 2023? The IND for the combination was cleared in May 2023 and we have now treated patients in the first two cohorts. In addition, we have received Fast Track designation by the FDA in September 2023 highlighting the impact this combination treatment can have for patients.

Food and Drug Administration 84

Food and Drug Administration Patients Safety Medical science 84